Drug
Quisinostat
Quisinostat is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Ph early_phase_1
1
25%
Ph phase_1
1
25%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 22 (50.0%)
Trials by Status
active_not_recruiting125%
recruiting125%
completed250%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruitingearly_phase_1
Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas
NCT06824662
recruitingphase_2
Adjuvant Quisinostat in High-Risk Uveal Melanoma
NCT06932757
completedphase_2
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
NCT02948075
completedphase_1
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
NCT02728492
Clinical Trials (4)
Showing 4 of 4 trials
NCT06824662Early Phase 1
Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas
NCT06932757Phase 2
Adjuvant Quisinostat in High-Risk Uveal Melanoma
NCT02948075Phase 2
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
NCT02728492Phase 1
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4